Trials / Suspended
SuspendedNCT06709131
A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia
A Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Status
- Suspended
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- He Huang · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Detailed description
This is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety, efficacy, and cellular pharmacokinetics of CT0991 in patients with relapsed or refractory acute myeloid leukemia. It is planned to enroll 9-24 participants in this trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAR-T cells（ chimeric antigen receptor T cells） | CAR-T cells（ chimeric antigen receptor T cells） |
Timeline
- Start date
- 2025-01-08
- Primary completion
- 2025-08-17
- Completion
- 2026-08-17
- First posted
- 2024-11-29
- Last updated
- 2025-11-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06709131. Inclusion in this directory is not an endorsement.